Drugmaker MAP Pharmaceuticals says that their inhaled migraine medication Levadex met all four of the study's goals in a recent clinical trial. The drug, formerly called MAP0004, was better than a placebo at controlling symptoms of pain, nausea, and sensitivity to light. Researchers also say the study on 792 patients found that Levadex reduced pain in half an hour, and sustained pain relief for 48 hours without showing any serious adverse effects. Levadex is an inhaled version of an older...
Read moreMy yearly routine includes talking to school staff about my son's asthma, filling out the appropriate forms and double-checking where his... Read more »
I went on a field trip to Poughkeepsie New York to the Culinary Institute of America last week. I went to meet a Chef colleague and have... Read more »
Should inhaled insulin be approved? According to the FDA, the answer appear to be no. Here’s the skinny on Afrezza. Afrezza is a... Read more »
Tick...tick...tick...Do you hear it? That's the sound of the clock ticking down to December 31, 2008 - the day some of the inhaled... Read more »
It would be neat if asthma was like a sport. Instead of writing dry, humorless posts, we could write exciting and entertaining posts... Read more »
A new inhaled migraine med has shown promising results in recent clinical trials. The medication, called Tempo, was found to provide significant pain... Read more »
Alexza Pharmaceuticals Inc. has announced that a new formula of a migraine drug has performed well in a recent test. Prochlorperazine currently is... Read more »
An orally-inhaled migraine medication called Levadex may help ease symptoms, a new Phase III study suggests. The study, funded by the drugmaker,... Read more »
Inhaled steroids may be a better choice than oral steroids for children with asthma, a new study suggests. Researchers from the University of New... Read more »
This is a study to compare the safety and effectiveness of a combination of prandial inhaled insulin and metformin with the inhaled insulin and a... Read more »